Recent Progress in Immunotherapy for RRMM: Updates from EHA 2023 Congress
Saved in:
| Main Author: | María-Victoria Mateos |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2023-06-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2023.16.111 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Highlights in Multiple Myeloma Treatment from EHA2021
by: Carmen de Ramon Ortiz
Published: (2021-10-01) -
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
by: Oren Pasvolsky, et al.
Published: (2025-05-01) -
CLL and Lymphoma Studies at EHA2021 and 16-ICML
by: Davide Rossi
Published: (2021-10-01) -
A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)
by: Chandramouli Nagarajan, et al.
Published: (2025-06-01) -
Highlights in CAR T-Cell Therapy from EHA2021: Paving the Way for Better Treatments
by: Federico Simonetta
Published: (2021-10-01)